PRME Earnings & Financial Statements
Prime Medicine, Inc.
$3.99
+$0.41(+11.45%)
62
Overall
55
Value
91
Tech
42
Quality
Market Cap
$723.69M
Volume
8.06M
52W Range
$2.67 - $6.94
Target Price
$7.02
PRME earnings and financial statements: Prime Medicine, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PRME Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.63M | $2.98M | $168.0K | $294.0K |
| Operating income | -$208.35M | -$202.47M | -$204.79M | -$116.54M |
| EBITDA | -$184.12M | -$177.40M | -$184.38M | -$114.32M |
| Net income | -$201.14M | -$195.88M | -$198.13M | -$121.82M |
| EPS (diluted) | $-1.35 | $-1.65 | $-2.18 | $-4.19 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $342.73M | $297.51M | $193.85M | $360.31M |
| Total liabilities | $221.87M | $144.36M | $60.78M | $44.04M |
| Shareholders’ equity | $120.87M | $153.15M | $133.07M | $316.27M |
| Cash and equivalents | $63.03M | $182.48M | $41.57M | $187.62M |
| Long-term debt | $108.29M | $37.18M | $4.36M | $17.05M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$162.56M | -$122.86M | -$165.41M | -$131.83M |
| Capital expenditure | -$4.53M | -$7.29M | -$8.72M | -$16.09M |
| Free cash flow | -$167.09M | -$130.16M | -$174.14M | -$147.92M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRME | $3.99 | +11.5% | 8.06M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |